Sir, Quinolones with enhanced activity against Streptococcus pneumoniae are included as a treatment option for communityacquired pneumonia in therapeutic guidelines from both North America and Europe, 1,2 and epidemiological surveys show that resistance to levofloxacin or moxifloxacin remains low even with large usage of these antibiotics.
Sir, Quinolones with enhanced activity against Streptococcus pneumoniae are included as a treatment option for communityacquired pneumonia in therapeutic guidelines from both North America and Europe, 1, 2 and epidemiological surveys show that resistance to levofloxacin or moxifloxacin remains low even with large usage of these antibiotics. 3 Yet, S. pneumoniae harbours efflux transporters for quinolones 4, 5 that may reduce the susceptibility of clinical isolates in a manner that will remain undetected if reporting is based only on the interpretative criteria proposed by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) or the US CLSI. While efflux in S. pneumoniae seems to primarily affect ciprofloxacin and norfloxacin (which are not recommended for treating infections caused by S. pneumoniae), much less is known about the susceptibility of novel quinolones to these transporters in current clinical isolates.
In the present study, we collected 183 non-duplicate isolates from patients with confirmed clinical and radiological diagnosis of community-acquired pneumonia during the 2007 -09 period. We measured the MICs of ciprofloxacin, levofloxacin, moxifloxacin and the two new quinolones garenoxacin and gemifloxacin for these isolates. We followed exactly the CLSI methodology except that we used 0.5 log 2 concentration increments to reduce the intrinsic 1 log 2 dilution error associated with the conventional methods of MIC determinations, and performed the determinations in the presence or absence of reserpine (10 mg/L; commonly used to detect the efflux-mediated decrease in susceptibility of S. pneumoniae to quinolones). 6 The results are shown in the left-hand panels of Figure 1 . In the absence of reserpine, median MICs were 1 mg/L of ciprofloxacin, 0.75 mg/L of levofloxacin, 0.125 mg/L of moxifloxacin, 0.047 mg/L of garenoxacin and 0.012 mg/L of gemifloxacin [see Table S1 , available as Supplementary data at JAC Online, for more numerical data (MIC range, MIC 50 and MIC 90 )]. All strains should be considered as susceptible to levofloxacin and moxifloxacin (using either the EUCAST or CLSI breakpoints) and also to gemifloxacin for 181/183 strains (using the CLSI breakpoint; no EUCAST breakpoint defined). In the presence of reserpine, the MIC distributions of ciprofloxacin, garenoxacin and gemifloxacin were markedly shifted towards lower values, with median values lowered by 1 log 2 dilution for ciprofloxacin and gemifloxacin, and 0.5 log 2 dilution for garenoxacin. In contrast, only minor shifts in distribution were seen for levofloxacin and moxifloxacin. To get further insight into the impact of efflux on the decrease in bacterial susceptibility to each quinolone, we calculated the MIC change for each isolate (by decrements of 0.5 log 2 dilutions) and present the results as a function of the original MIC (without reserpine) in the right-hand panels of Figure 1 . For ciprofloxacin, 93.4% of the strains had an MIC ≥ 0.75 mg/L, with 29.2% of these showing a difference of more than 1 log 2 dilution upon exposure to reserpine. For gemifloxacin, reserpine caused an increase in susceptibility of ≥1 log 2 dilution in 65% of the isolates with a basal MIC (in the absence of reserpine) ≥0.006 mg/L. For garenoxacin, the susceptibility of 60% of the isolates was increased in the presence of reserpine (this was seen whatever the basal MIC), but the effect rarely exceeded 1 log 2 dilution. For moxifloxacin and levofloxacin, increases in susceptibility were seen for 39% and 45% of the isolates, respectively, but affecting mainly the strains with a corresponding basal MIC ≥0.188 mg/L (moxifloxacin) or ≥0.75 mg/L (levofloxacin). The shift was ,1 log 2 dilution in 59% of the isolates for moxifloxacin and in 86% for levofloxacin.
The data strongly suggest that gemifloxacin and ciprofloxacin are both subject to efflux in S. pneumoniae. Of interest is the fact that gemifloxacin has so far not been used in Europe and could, therefore, not have triggered its own efflux. Ciprofloxacin has never been included in therapeutic recommendations for treatment of streptococcal infections in Belgium. We may suspect that it is its wide use for other indications that has triggered the emergence of S. pneumoniae strains capable of developing efflux-mediated resistance to ciprofloxacin through repeated exposure to subinhibitory concentrations of this antibiotic. 6 It is ironic that this affects gemifloxacin, a not-yet-used but potentially very active antibiotic, even though not all isolates were positive in our assay. Since efflux is known to facilitate the selection of first-step mutants amongst fluoroquinolone-susceptible organisms, our data must be taken as a warning should gemifloxacin be introduced on a wide scale in therapeutics. In a more general context, and based on the observation that strains with efflux may be quite frequent, surveillance studies for the detection of new variants of efflux transporters affecting levofloxacin and moxifloxacin may be warranted. This could have a direct clinical significance if those strains, as recently suggested, 5 were also to show mutations or other low-level mechanism(s) of resistance. Table S1 is available as Supplementary data at JAC Online (http://jac. oxfordjournals.org/). Rifampicin is a potent inducer of the UGT1A1 enzyme, the principal route of elimination of raltegravir. Pharmacokinetic studies in healthy volunteers 2 and in HIV-infected patients with TB 3 have been performed. In them, the AUC of raltegravir, with the usual dose (400 mg twice daily), was reduced by 40% due to UGT1A1 induction by rifampicin. Doubling the dose of raltegravir (800 mg twice daily) offset this effect, resulting in an increase in the AUC of 27%.
Supplementary data
Recently Merck reported initial results from the MK-0518-071 study in which two doses of raltegravir were compared, 400 mg twice daily versus 800 mg once daily, in combination with tenofovir/emtricitabine in adult treatment-naive HIV-1-infected patients. After 48 weeks, raltegravir once daily did not demonstrate non-inferiority to the regimen with raltegravir twice daily. These results suggest that there could be a high risk of virological failure if levels of raltegravir are too low.
Herein we report our experience with eight HIV-positive patients diagnosed with TB and treated with rifampicin-containing tuberculostatic regimens and raltegravir-containing ART. The median age was 47 years (range 33-49) and six of the patients were men (75%). Risk factors for HIV infection were as follows: six injection drugs users; and two men who have sex with men. The CDC categories, before the diagnosis of TB, were as follows: category A, 4; category B, 1; and category C, 3. Median follow-up of HIV was 15 years (range 1-21) and 6 patients had hepatitis C virus (HCV) co-infection. Four were receiving methadone maintenance treatment.
At the diagnosis of TB, four patients were undergoing ART, and all treatments included boosted PIs (three atazanavir/ritonavir and one darunavir/ritonavir); all of these patients had HIV-RNA ,20 copies/mL and the median CD4 count was 332 cells/mm 3 (range 236-589). They did not interrupt ART, but the boosted PI was changed for raltegravir (800 mg twice daily) and continued with the same backbone (three tenofovir/emtricitabine and one abacavir/lamivudine). For the four patients not on ART, the mean HIV-RNA was 5+0.8 log 10 copies/mL and the median CD4 count was 118 cells/mm 3 (range 9-224). This group started with ART 56+22 days after beginning anti-TB drugs; the ART was tenofovir/ emtricitabine and raltegravir (800 mg twice daily) in all cases.
The location of TB, treatment and outcome are shown in Table 1 . During the follow-up, no cases of immune reconstitution inflammatory syndrome were found. All patients were monitored at the beginning of TB treatment in order to discard toxicity, mainly hepatic and myopathy, and every 2 or 3 months. The safety profile of TB treatment and ART was good; no adverse events due to TB treatment and ART were documented. It was not necessary to stop or change any of the drugs, and all the subjects finished the TB treatment with the same ART and continued it after.
At the end of TB treatment, all patients previously taking ART remained with HIV-RNA ,20 copies/mL and the median CD4 count was 455 cells/mm 3 (range 268-666). In those who were not under ART when TB was diagnosed, HIV-RNA was undetectable in all cases and the median CD4 count was 238 cells/mm 3 (range 208 -265). We did not find virological rebounds during the follow-up.
To our knowledge, these are the first clinical data reported on the use of raltegravir as part of ART in subjects taking rifampicin 
